Menu

Search

  |   Business

Menu

  |   Business

Search

Cognition Therapeutics CEO Kenneth I. Moch to Present at the Stifel 2017 Healthcare Conference

Pittsburgh, Nov. 08, 2017 -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of Alzheimer’s disease and other neurocognitive disorders, today announced that President & CEO Kenneth I. Moch will present at the Stifel 2017 Healthcare Conference at 8:45 a.m. on November 15, 2017 at the Lotte New York Palace Hotel.

Mr. Moch’s presentation will include a corporate update as well as summary of results from the company’s Phase 1b/2a study of CT1812 in patients with mild-to-moderate Alzheimer’s disease. These results, which were recently presented at the annual Clinical Trials on Alzheimer’s Disease (CTAD) conference, showed that CT1812 was well tolerated and generated a differential change compared to placebo in the levels of several key cerebrospinal fluid proteins that are dysregulated in Alzheimer’s disease.

About CT1812
Cognition’s lead product candidate, CT1812, has completed a Phase 1b/2a clinical study (COG0102) in patients with mild-to-moderate Alzheimer’s disease and has been granted Fast Track designation by the US FDA. This highly brain penetrant compound targets the sigma-2 receptor complex on neuronal synapses, displacing toxic beta amyloid (Aβ) oligomers from their binding sites on brain cells and clearing them into the cerebrospinal fluid. CT1812 has been shown in multiple Alzheimer’s disease models to stop memory loss. Study COG0102 was supported in part under Award Number RF1AG054176 from The National Institute on Aging of the National Institutes of Health.

About Cognition Therapeutics, Inc.
Cognition Therapeutics is a privately held biopharmaceutical company developing a pipeline of disease modifying small molecule drug candidates to treat neurocognitive disorders. Cognition’s lead candidate, CT1812, is a proprietary first-in-class, orally available small molecule in development for the treatment of mild-to-moderate Alzheimer’s disease. CT1812 and Cognition’s other pipeline candidates were identified using the company’s disease-relevant screening and novel chemistry platforms. Additional information about Cognition and its product candidates may be found online at http://www.cogrx.com.

Forward-Looking Statements
This press release contains “forward-looking statements” concerning the development and commercialization of Cognition’s products, the potential benefits and attributes of such products, and Cognition’s expectations regarding its prospects. Forward-looking statements are subject to risks, assumptions and uncertainties that could cause actual future events or results to differ materially from such statements. These statements are made as of the date of this press release. Actual results may vary. Cognition undertakes no obligation to update any forward-looking statements for any reason.

Cognition Therapeutics
[email protected]
412-465-0095

Aline Sherwood
Scienta Communications
[email protected] 
312-238-8957

  • ET PRO
  • Market Data

Market-moving news and views, 24 hours a day >

June 14 14:00 UTC Released

USYr Inf Prelim

Actual

2.2 %

Forecast

Previous

2.6 %

June 14 14:00 UTC Released

USU Mich 1Yr Inf Prelim

Actual

2.6 %

Forecast

Previous

2.9 %

January 31 00:00 UTC 721772721772m

ARAnnual Primary Balance*

Actual

Forecast

2016 bln ARS

Previous

Bln AR bln ARS

January 31 00:00 UTC 721772721772m

ARAnnual Primary Balance*

Actual

Forecast

2016 bln ARS

Previous

Bln AR bln ARS

January 22 19:00 UTC 733592733592m

ARTrade Balance

Actual

Forecast

Previous

-1541 %

January 31 00:00 UTC 721772721772m

ARAnnual Primary Balance*

Actual

Forecast

2016 bln ARS

Previous

Bln AR bln ARS

January 22 19:00 UTC 733592733592m

ARTrade Balance

Actual

Forecast

Previous

-1541 %

January 31 00:00 UTC 721772721772m

ARAnnual Primary Balance*

Actual

Forecast

2016 bln ARS

Previous

Bln AR bln ARS

January 31 00:00 UTC 721772721772m

ARAnnual Primary Balance*

Actual

Forecast

2016 bln ARS

Previous

Bln AR bln ARS

January 31 00:00 UTC 721772721772m

ARAnnual Primary Balance*

Actual

Forecast

2016 bln ARS

Previous

Bln AR bln ARS

Close

Welcome to EconoTimes

Sign up for daily updates for the most important
stories unfolding in the global economy.